Coherus Bio (CHRS)

$0.78 +0.02 (2.09%)
Market Cap 90.31M
Revenue (ttm) 266.96M
Net Income (ttm) 28.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 10.68%
Debt to Equity Ratio -0.20
Volume 1,822,400
Avg Vol 1,708,078
Day's Range N/A - N/A
Shares Out 115.93M
Stochastic %K 30%
Beta 1.01
Analysts Strong Sell
Price Target $5.26

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigat...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 649 3530
Address:
333 Twin Dolphin Drive, Suite 600, Redwood City, United States
MajorMoney
MajorMoney Dec. 25 at 8:54 AM
$CHRS Expectations reset as evidence replaces narrative, because growth without leverage now attracts skepticism. A coherent operating roadmap would be catalytic.
1 · Reply
GoWhiteSox
GoWhiteSox Dec. 24 at 1:32 PM
$CHRS https://www.researchgate.net/publication/398955785_CHS-114_an_afucosylated_anti-CCR8_monoclonal_antibody_that_selectively_depletes_intratumoral_Treg_cells_and_induces_antitumor_immune_responses
0 · Reply
Cowpokecaleb
Cowpokecaleb Dec. 24 at 1:19 PM
$CHRS https://seekingalpha.com/article/4855400-coherus-oncology-a-two-pronged-march-with-mid-2026-implications
0 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Dec. 23 at 10:24 PM
$CHRS coherus last year sent out a pr one week before. Unless something changes, jpm will be similar to the other coherus fireside chats. No clinical data til asco in June (likely) and biomarker data doesn't move the stock up. One hope is where is Denny +? If any deal is coming, it should come by jpm IMHO.
0 · Reply
Moneyaintfree
Moneyaintfree Dec. 23 at 9:11 PM
$CHRS steady increase in volume today
0 · Reply
calibran_de
calibran_de Dec. 23 at 6:55 PM
$CHRS I added a few more shares today!
0 · Reply
BigDaddyCapital
BigDaddyCapital Dec. 23 at 4:49 PM
$CHRS buy orders set $1.25
0 · Reply
BigDaddyCapital
BigDaddyCapital Dec. 23 at 4:43 PM
$CHRS low volume & massive sell order, could get sub $1.30
0 · Reply
Jalu06
Jalu06 Dec. 23 at 3:30 PM
$CHRS Coherus time slot at JPM26 is on January 13th 10.30 am PT
1 · Reply
Sarandon
Sarandon Dec. 23 at 2:50 PM
$CHRS Potential multi-day runner. 🩳🔥🚀 It's inevitable, it's gradually going up. Minimum target: $4 during 2026. "In this exploratory post-hoc analysis, patients receiving LOQTORZI plus gemcitabine and cisplatin achieved a median OS of 64.8 months, nearly double that of chemotherapy alone (33.7 months), representing a 31-month improvement and an observed 38% reduction in risk of death (HR 0.62; 95% CI, 0.45–0.85). Recommended to watch today: $TRIP $OPTX $HIHO $RVPH
1 · Reply
Latest News on CHRS
Coherus Oncology: A Two-Pronged March With Mid-2026 Implications

Dec 23, 2025, 11:06 AM EST - 1 day ago

Coherus Oncology: A Two-Pronged March With Mid-2026 Implications

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Dec 8, 2025, 8:30 AM EST - 17 days ago

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 5:01 PM EST - 6 weeks ago

Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 5:56 PM EST - 6 weeks ago

Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Nov 7, 2025, 9:00 AM EST - 6 weeks ago

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 4:14 PM EST - 6 weeks ago

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Nov 6, 2025, 1:54 PM EST - 6 weeks ago

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 30, 2025, 8:30 AM EDT - 2 months ago

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Coherus Oncology to Participate in Upcoming Investor Conferences

Oct 23, 2025, 8:30 AM EDT - 2 months ago

Coherus Oncology to Participate in Upcoming Investor Conferences

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

Oct 10, 2025, 4:32 AM EDT - 2 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX ALEC BDTX

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 3, 2025, 9:05 AM EDT - 2 months ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

Oct 1, 2025, 5:02 PM EDT - 3 months ago

Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

Coherus Oncology: Five Readouts Or More Possible In 2026

Oct 1, 2025, 10:43 AM EDT - 3 months ago

Coherus Oncology: Five Readouts Or More Possible In 2026

Coherus Oncology: On The Shaping Up

Aug 25, 2025, 4:55 PM EDT - 4 months ago

Coherus Oncology: On The Shaping Up

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 11:35 AM EDT - 4 months ago

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 4:41 PM EDT - 4 months ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 31, 2025, 4:45 PM EDT - 5 months ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:46 PM EDT - 8 months ago

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:15 PM EDT - 8 months ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 5, 2025, 4:01 PM EDT - 8 months ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

Coherus to Participate in Upcoming Investor Conferences

May 1, 2025, 5:04 PM EDT - 8 months ago

Coherus to Participate in Upcoming Investor Conferences

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 28, 2025, 10:10 AM EDT - 8 months ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Apr 17, 2025, 5:53 AM EDT - 9 months ago

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Apr 14, 2025, 8:00 AM EDT - 9 months ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 9 months ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 8:52 PM EDT - 10 months ago

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 4:12 PM EDT - 10 months ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Mar 3, 2025, 8:30 AM EST - 10 months ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Feb 24, 2025, 9:08 AM EST - 10 months ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 18, 2024, 8:30 AM EST - 1 year ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 16, 2024, 6:08 PM EST - 1 year ago

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Dec 3, 2024, 9:34 AM EST - 1 year ago

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 27, 2024, 4:01 PM EST - 1 year ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:09 PM EST - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:01 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13, 2024, 10:01 AM EDT - 1 year ago

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 6:08 PM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Aug 1, 2024, 9:00 AM EDT - 1 year ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Jun 27, 2024, 8:26 AM EDT - 1 year ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31, 2024, 12:04 PM EDT - 1 year ago

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 30, 2024, 9:00 AM EDT - 1 year ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 5:51 PM EDT - 1 year ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 23, 2024, 9:00 AM EDT - 1 year ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript

May 10, 2024, 12:07 AM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:01 PM EDT - 1 year ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

May 9, 2024, 7:30 AM EDT - 1 year ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 8, 2024, 9:00 AM EDT - 1 year ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

May 1, 2024, 4:30 PM EDT - 1 year ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 10:02 AM EDT - 1 year ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

MajorMoney
MajorMoney Dec. 25 at 8:54 AM
$CHRS Expectations reset as evidence replaces narrative, because growth without leverage now attracts skepticism. A coherent operating roadmap would be catalytic.
1 · Reply
GoWhiteSox
GoWhiteSox Dec. 24 at 1:32 PM
$CHRS https://www.researchgate.net/publication/398955785_CHS-114_an_afucosylated_anti-CCR8_monoclonal_antibody_that_selectively_depletes_intratumoral_Treg_cells_and_induces_antitumor_immune_responses
0 · Reply
Cowpokecaleb
Cowpokecaleb Dec. 24 at 1:19 PM
$CHRS https://seekingalpha.com/article/4855400-coherus-oncology-a-two-pronged-march-with-mid-2026-implications
0 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Dec. 23 at 10:24 PM
$CHRS coherus last year sent out a pr one week before. Unless something changes, jpm will be similar to the other coherus fireside chats. No clinical data til asco in June (likely) and biomarker data doesn't move the stock up. One hope is where is Denny +? If any deal is coming, it should come by jpm IMHO.
0 · Reply
Moneyaintfree
Moneyaintfree Dec. 23 at 9:11 PM
$CHRS steady increase in volume today
0 · Reply
calibran_de
calibran_de Dec. 23 at 6:55 PM
$CHRS I added a few more shares today!
0 · Reply
BigDaddyCapital
BigDaddyCapital Dec. 23 at 4:49 PM
$CHRS buy orders set $1.25
0 · Reply
BigDaddyCapital
BigDaddyCapital Dec. 23 at 4:43 PM
$CHRS low volume & massive sell order, could get sub $1.30
0 · Reply
Jalu06
Jalu06 Dec. 23 at 3:30 PM
$CHRS Coherus time slot at JPM26 is on January 13th 10.30 am PT
1 · Reply
Sarandon
Sarandon Dec. 23 at 2:50 PM
$CHRS Potential multi-day runner. 🩳🔥🚀 It's inevitable, it's gradually going up. Minimum target: $4 during 2026. "In this exploratory post-hoc analysis, patients receiving LOQTORZI plus gemcitabine and cisplatin achieved a median OS of 64.8 months, nearly double that of chemotherapy alone (33.7 months), representing a 31-month improvement and an observed 38% reduction in risk of death (HR 0.62; 95% CI, 0.45–0.85). Recommended to watch today: $TRIP $OPTX $HIHO $RVPH
1 · Reply
calibran_de
calibran_de Dec. 23 at 11:43 AM
$CHRS
0 · Reply
Henry20feb_
Henry20feb_ Dec. 23 at 9:21 AM
$CHRS 5.000 watchers - another milestone achieved! 🥳
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 22 at 11:28 PM
$CHRS Share Price: $1.40 Contract Selected: Aug 21, 2026 $2.0 Calls Buy Zone: $0.21 – $0.26 Target Zone: $0.36 – $0.44 Potential Upside: 59% ROI Time to Expiration: 241 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
whateverhappenedthere
whateverhappenedthere Dec. 22 at 9:10 PM
$CHRS tagmo ex US licensees to Denny
1 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Dec. 22 at 5:43 PM
$CHRS there is no wall. Chrs is a pennystock so 100k can drop it 5%. But zero volume right now which is good if we melt up. Hopefully we just melt back to 1.89 over the next week. ANYONE KNOW WHY DENNY MISSED BAIRD VIRTUAL MEETING? Anyone remember any fireside without Denny. (I checked and can't find one) HE COULD HAVE DROPPED IN AS IT WAS VIRTUAL.
0 · Reply
Moneyaintfree
Moneyaintfree Dec. 22 at 5:00 PM
$CHRS anyone has the ability to see the wall at 1.42?
0 · Reply
Sarandon
Sarandon Dec. 22 at 2:48 PM
$CHRS 🚀🚀🚀🚀
0 · Reply
cjwashington
cjwashington Dec. 22 at 2:21 PM
$CHRS
0 · Reply
TXborn
TXborn Dec. 21 at 2:04 PM
$CHRS ASCO GI 2026 Coherus is listed to present translational biomarker data from its Phase 2 unresectable HCC study (casdozokitug with PD-1). Last year they did a PR confirming conference participation, so worth keeping an eye out next week.
1 · Reply
calibran_de
calibran_de Dec. 20 at 10:50 PM
$CHRS https://trial.medpath.com/news/b74dcf3f561755a2/coherus-biosciences-rebrands-as-coherus-oncology-advances-immuno-oncology-pipeline-with-novel-combination-therapies
0 · Reply
Fomoninja
Fomoninja Dec. 20 at 8:33 PM
$CHRS Good news! We have a short gone, bye-bye. Down to 4 short from 5. LFG!
1 · Reply
Jbaffs
Jbaffs Dec. 19 at 6:01 PM
$CHRS $2 in January
0 · Reply